Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research

Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research

Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research

Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research

Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research

Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research

Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research

Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research

Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research

Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research

Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research

Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research

Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research

Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results from a Randomized Controlled Clinical Trial
Iran J Allergy Asthma Immunol. 2024 Feb 11;23(1):82-96. doi: 10.18502/ijaai.v23i1.14956.ABSTRACTThe severe coronavirus disease 2019 (COVID-19) is associated with increased levels of blood interleukin (IL)-6. Therefore, it is hypothesized that modulating the levels or effects of IL-6 could diminish airway inflammation and alter the course of COVID-19. We conducted a controlled, randomized, double-blind clinical trial on hospitalized patients with severe COVID-19 in Iran. The patients were randomly distributed by block randomization to take either standard-of-care (SOC) plus 1 or 2 doses of tocilizumab 8 mg/kg or SOC alone. ...
Source: Iranian Journal of Allergy, Asthma and Immunology - March 15, 2024 Category: Allergy & Immunology Authors: Mona Talaschian Maryam Akhtari Mahdi Mahmoudi Shayan Mostafaei Mohamadreza Jafary Seyyed Mostafa Jalali Kourosh Sadeghi Keivan Gohari Moghadam Hengameh Ansari Tadi Ahmadreza Jamshidi Source Type: research